| Name | Title | Contact Details |
|---|
IMTEC Corp (Main) US HQ is a Ardmore, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Q Macs is a Richardson, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CHF Solutions is an early stage company focused on commercializing the Aquadex FlexFlow system. Our objective is to improve the quality of life for patients with heart failure and related conditions, such as fluid overload. At CHF Solutions, we are committed to the relentless pursuit of identifying and developing innovative solutions to address unmet clinical needs with the goal of benefiting patients, medical practitioners, and the broader healthcare community.
At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.
Procyrion is developing the first catheter-deployed circulatory assist device intended for long-term use. The Procyrion device will be the first minimally invasive tool for cardiologists to treat over 1M NYHA Class III and early class IV heart failure (HF) patients in the US who have few therapeutic options. In partnership with Texas Heart Institute, Procyrion is currently conducting preclinical testing of the Procyrion device.